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AbstrACt
Introduction In January 2017, mifepristone-induced medical 
abortion was made available in Canada. In this study, we 
will seek to (1) understand facilitators and barriers to the 
implementation of mifepristone across Canada, (2) assess the 
impact of a ‘community of practice’ clinical and health service 
support platform and (3) engage in and assess the impact 
of integrated knowledge translation (iKT) activities aimed to 
improve health policy, systems and service delivery issues to 
enhance patient access to mifepristone.
Methods and analysis This prospective mixed-methods 
implementation study will involve a national sample of 
physicians and pharmacists recruited via an online training 
programme, professional networks and a purpose-built 
community of practice website. Surveys that explore 
constructs related to diffusion of innovation and Godin’s 
behaviour change frameworks will be conducted at 
baseline and at 6 months, and qualitative data will be 
collected from electronic interactions on the website. 
Survey participants and a purposeful sample of decision-
makers will be invited to participate in in-depth interviews. 
Descriptive analyses will be conducted for quantitative 
data. Thematic analysis guided by the theoretical 
frameworks will guide interpretation of qualitative data. 
We will conduct and assess iKT activities involving 
Canada’s leading health system and health professional 
leaders, including evidence briefs, Geographical 
Information System (GIS)maps, face-to-face meetings 
and regular electronic exchanges. Findings will contribute 
to understanding the mechanisms of iKT relationships 
and activities that have a meaningful effect on uptake of 
evidence into policy and practice.
Ethics and dissemination Ethical approval was received 
from the University of British Columbia Children’s and 
Women’s Hospital Ethics Review Board (H16-01006). Full 
publication of the work will be sought in an international 
peer-reviewed journal. Findings will be disseminated to 
research participants through newsletters and media 
interviews, and to policy-makers through invited evidence 
briefs and face-to-face presentations.
IntroduCtIon   
Induced abortion is a common, safe and legal 
reproductive health procedure in Canada, 
with nearly one in three Canadian women 
having at least one abortion during their 
reproductive years.1–3 However, access to 
abortion is not equitable. In 2012, 96% of 
Canadian abortions were performed using 
surgery, through fewer than 100 facilities, 
located primarily in Canada’s largest cities 
within 150 km of the US border.3 4 Histori-
cally in Canada, abortion provision has been 
included within the scope of practice only 
for physicians, and in 2012, it was offered by 
fewer than 300 doctors.3 5 Under these condi-
tions, patients living outside of major cities 
had to travel inordinate distances to reach 
service locations, experienced significant wait 
times and faced numerous barriers to equi-
table access to abortion service.6 7 Notably, 
The United Nations Human Rights Commis-
sioner’s November 2016 Report of the 
Committee on Elimination of Discrimination 
Against Women expressed concern over ineq-
uitable abortion access in Canada and called 
strengths and limitations of this study
 ► The mixed-methods design of this study will pro-
vide qualitative evidence to enrich the quantitative 
results and corroborate knowledge about the effect 
of health policy, system and service determinants on 
access to medical abortion.
 ► The potential of our research to make an impact on 
policy and practice is strengthened by an integrated 
knowledge translation approach (iKT), where deci-
sion-makers and practitioners are actively involved 
in collecting, analysing and interpreting our study 
data.
 ► Evaluation of our iKT approach of having deci-
sion-makers on the research team will contribute 
critical knowledge on which strategies are most 
effective at facilitating coproduced knowledge, mit-
igating barriers and improving equitable access to 
abortion.
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on the government of Canada to demonstrate improve-
ment.8 Canada’s federal drug regulator, Health Canada, 
approved mifepristone, the gold standard for medical 
abortion,5 in July of 2015.9 Subsequently, mifepristone 
first became available to Canadians on 10 January 2017.10 
Mifepristone was first introduced to the global market-
place in 1988. In other nations, the drug has not been 
associated with an increase in overall abortion rates, 
while it has increased the proportion of medical abortion 
compared with surgical.11 Widely differing rates of mife-
pristone implementation, particularly in primary care 
settings, have been noted worldwide among countries with 
approval.11–16 Uptake in the USA was among the slowest: 
at 10 years after approval, only 10% of all abortions were 
provided by mifepristone, compared with 70% in Scotland 
and 80% in Northern Europe.11 13 14 16 Variation in health 
systems, provider training, provider support, drug regu-
lations and legislated restrictions may account for these 
differences. Canada’s geographical disparities in access 
to abortion care, particularly among rural and remote 
populations, call for innovative approaches to the imple-
mentation of mifepristone services, including strategies 
to support primary care providers to initiate and sustain 
abortion services. Mifepristone implementation has the 
potential to address current abortion service disparities 
and health access inequities, particularly among disad-
vantaged populations.
When mifepristone was approved in Canada, Health 
Canada specified several unique restrictions that could 
act as significant barriers to access. Namely, only physi-
cians may prescribe and dispense mifepristone, and that 
those who provide mifepristone must be certified through 
an accredited online training programme.9 17 Our multi-
disciplinary research team theorises that mifepristone 
training and practice could be undertaken by a range of 
healthcare professionals who are interested in providing 
mifepristone, including family physicians, nurse practi-
tioners and midwives. Further, we postulate that, based 
on the above-cited evidence from international settings, 
mandatory training and certification without additional 
practice support will be insufficient to facilitate adop-
tion and distribution of this innovation in the face of the 
federal restrictions, particularly among primary health-
care professionals in rural areas and/or without prior 
experience providing abortion. We further hypothesise 
that the identification and mitigation of implementation 
barriers and facilitators at the health policy, system and 
service delivery levels, particularly those affecting primary 
care providers, could advance mifepristone practice in 
Canada and improve equitable abortion care access.
Our study is informed by principles of integrated 
knowledge translation (iKT)18 and Roger’s Theory of the 
Diffusion of Innovation19 in seeking to answer the ques-
tion: What are the factors that influence successful initia-
tion and ongoing provision of medical abortion services 
among health professionals, and how do these relate to 
health policies, systems, and services, and to abortion 
services access throughout Canada?
MEthods
Aims
The aims of this study are:
 ► To understand health policy, system and service facili-
tators and barriers to the distribution and implemen-
tation of mifepristone abortion practice in primary 
care.
 ► To assess the impact of a ‘community of practice’ plat-
form to detect and support clinical, health service and 
system challenges faced by clinicians adopting mife-
pristone medical abortion practice.
 ► To evaluate continuous iKT with and by health policy, 
health system, and health services decision-makers 
and health professional organisations to reduce 
barriers and optimise facilitators, for mifepristone 
abortion practice.
This study protocol is guided by the Standards for 
Reporting Implementation Studies statement.20
Conceptual frameworks
Our study uses a theoretical framework combining two 
theories to explain adoption and diffusion of innovations: 
Roger’s Theory of the Diffusion of Innovation and Godin’s 
framework. Greenhalgh et al19 developed constructs to 
capture determinants for implementation, as articulated 
by Rogers’ Theory of the Diffusion of Innovation,21 in 
health service delivery and health systems (see figure 1). 
This comprehensive theoretical model of dissemination 
and implementation of health service innovations aims 
to support research for bridging the gap between knowl-
edge and practice/policy. The model was developed from 
a systematic meta-narrative review of scientific evidence 
on factors related to implementation.19 It articulates 
key constructs for capturing the complex processes of 
implementation: characteristics of the innovation and 
adopter; methods of diffusion and dissemination (eg, 
communication and influence); system antecedents and 
readiness; outer context; resource systems and change 
Figure 1 Determinants of diffusion of innovations in health 
service delivery organisations, adapted from Greenhalgh et al.19
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agents; and their role in facilitating the implementation 
process.19 Cook et al operationalised these constructs into 
semistructured survey and interview questions to allow 
researchers to generate evidence on barriers and enablers 
to implementation.22
Within these constructs, we further explore provider 
uptake and behaviours using Godin et al’s framework,23 
integrating the theory of planned behaviour24 and 
Triandis’ theory,25 to predict intention and uptake of clin-
ical behaviour. The strongest predictors of behaviour are 
intention, belief about capabilities, and frequency of past 
behaviour. Intention is influenced by belief about conse-
quences, role identity, moral norm, social influences and 
personal characteristics. This framework has good appli-
cation to practise in the abortion context, where role 
identity, moral norm and social factors could have strong 
influence on behaviour.26
design
We designed a prospective mixed-methods observational 
research study on factors that influence implementation 
of mifepristone in primary care over the initial 2 years 
of practice in Canada. We hypothesised that healthcare 
professionals interested in adopting mifepristone care 
into their practice would have widely varied professional 
characteristics, practice locations and settings, and local 
or health system supports, and would serve a wide variety 
of disadvantaged and vulnerable populations; all of which 
may influence implementation and access to care. Our 
national, interprofessional research team (nursing, medi-
cine, pharmacy, epidemiology, implementation science, 
medical sociology, computer science, public health and 
education) is composed of senior, mid and early career 
investigators, national and provincial policy-makers, 
healthcare and health professional organisations, clini-
cians, citizen groups and trainees. Our design is flexible 
and will be adapted in response to health system and 
policy changes. This will allow us to collect data in the 
setting, samples and contexts that may provide the richest 
information to answer our research questions.
health system intervention
Mifepristone is marketed, in combination with miso-
prostol in Canada, as Mifegymiso, for the indication of 
early medical abortion (one mifepristone 200 mg tablet 
and four misoprostol 200 µg tablets). Mifepristone is used 
in more than 60 countries worldwide, is on the WHO list 
of essential medicines,27 and has an excellent safety and 
effectiveness profile as illustrated by administration to 
millions of women.28–30
Mifepristone provided in primary care settings is an 
innovative health service delivery model for medical abor-
tion. Until now, high-income country drug regulators have 
placed a range of unique restrictions on the distribution 
and administration of mifepristone,31 32 which has largely 
limited provision of mifepristone to abortion providers 
in existing urban sexual and reproductive-specific health 
facilities that generally provide a high volume of surgical 
abortion services. In Australia, for instance, mifepristone 
by prescription that could be filled in a pharmacy was 
approved in 2012, but restrictions including provider 
and pharmacist training and certification limited initial 
uptake.33 Similar restrictions were approved in Canada as 
part of the initial 2015 drug approval9 17 (see box 1).
Nonetheless, mifepristone abortion delivered in primary 
care settings by physicians and other skilled providers has 
been shown to be safe and effective.12–14 28–30 34–36 In this 
context, we will seek to identify, initiate and evaluate two 
implementation strategies that aim to overcome clinical, 
health service and system challenges faced by clinicians 
adopting mifepristone medical abortion practice, partic-
ularly in primary care settings.
Implementation strategy
Community of practice platform
The central iKT strategy for this study is the collaborative 
interdisciplinary community of practice—with the objec-
tive of sharing real-time clinical best practices, dissemi-
nating information, advocating for and sharing policy 
changes to support timely and equitable access to mife-
pristone medical abortion by bringing together health 
providers, policy, and system partners and our team of 
investigators and knowledge users. As Wenger et al explain, 
‘communities of practice are groups of people who share 
a concern, a set of problems, or a passion about a topic, 
and who deepen their knowledge and expertise in this 
area by interacting on an ongoing basis.’37 The principle 
underlying communities of practice is that practitioners 
advance their skills and knowledge both on the job and 
off work through social relationships, rather than in class-
room settings.38 Social learning through a social struc-
ture facilitates learning a practice through interactions, 
relationships and sharing of resources and solutions to 
build skills and knowledge. The rationale for including 
a community of practice strategy was derived from the 
international literature on mifepristone practice in other 
high-income nations, and was reinforced by findings 
from focus group research involving Canadian physicians 
in which we developed and pilot tested the survey for this 
present study.39 40
We created a community of practice platform for 
the present study: the Canadian Abortion Providers 
Support-Communauté de pratique canadienne sur l’avor-
tement (CAPS-CPCA), an internet accessible website. It 
box 1 Canadian restrictions for prescribing and 
dispensing mifepristone, July 2015
 ► Mandatory training for prescribers and pharmacists.
 ► Mandatory registration of prescribers and pharmacists with the 
manufacturer.
 ► Physician-only prescribing.
 ► Physician-only dispensing direct to the patient.
 ► Mandatory use of a manufacturer-provided consent form to be 
signed by the patient.
 ► Physician’s observation of mifepristone ingestion.
 o
n
 10 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028443 on 20 April 2019. Downloaded from 
4 Norman WV, et al. BMJ Open 2019;9:e028443. doi:10.1136/bmjopen-2018-028443
Open access 
is designed to encourage multidirectional interaction of 
healthcare professionals engaging in mifepristone prac-
tice with the experts and researchers and will promote 
sharing best practice resources and facilitators. Interactive 
pages (‘Ask an Expert’ and ‘Share a Case’) will promote 
a synchronised dialogue while resource pages (‘What’s 
happening in your province?’, ‘Locate a Pharmacy’ and 
‘Helpful Resources’) will provide practical, local knowl-
edge for members to apply in their individual practices. 
Members will be provided news updates on topics rele-
vant to mifepristone practice, such as practice tools, 
billing codes, regulation changes and universal coverage.
iKT activities
We follow the Canadian Institutes of Health Research 
definition of iKT, which describes it as ‘an approach to 
doing research that applies the principles of knowledge 
translation to the entire research process. The central 
premise of iKT is that involving knowledge users as equal 
partners alongside researchers will lead to research that 
is more relevant to, and more likely to be useful to, the 
knowledge users.’18 We anticipate that our iKT approach 
will more rapidly mitigate barriers and improve equitable 
access to abortion, with the assumption that stakeholders 
will be more likely to accept and act on coproduced 
knowledge.41 42 Using iKT processes to achieve particular 
objectives focuses researchers and stakeholders on the 
same page to create shared meaning, identify facilitators 
and barriers to the process of evidence implementation, 
and cocreate empirical knowledge to support health 
service planning. As a result, the partnership process itself 
is instrumental in implementing sustainable change.43 
The effect of iKT activities on research outcomes such 
as practice and policy change is still unclear, largely due 
to inconsistent description, evaluation and reporting 
in most studies.44 However, there is emerging evidence 
from Canada and the UK that iKT may lead to increased 
capacity to use research among knowledge users, greater 
relevance and usefulness of research evidence to knowl-
edge users, increased use of research in decision-making, 
and improved patient and health system outcomes.45
In the context of this study, our iKT activities are diverse, 
responsive and tailored to the needs and contexts of 
stakeholders. These activities include but are not limited 
to: invited evidence briefs, face-to-face meetings, media 
interviews, minutes documenting interactions within 
monthly multidisciplinary team video-conferenced meet-
ings and an annual national collaboration meeting. Face-
to-face interaction will optimise relationships, apprise 
knowledge users of progress and ensure the flow of ideas. 
Both clinician and policy-maker knowledge users will be 
welcomed to join our monthly meetings, to contribute 
actively to the evaluation and interpretation of data 
collected each month, and to plan to address identified 
barriers and facilitators in real time. Knowledge users 
may identify colleagues for face-to-face meetings relevant 
to specific phases of the project. Our meeting agendas 
will address topics from policy development, to education 
input, to practice. Our investigators and knowledge users 
will be invited to convey results to other knowledge user 
organisations, such as: health professional development 
at national, provincial and regional health professional 
meetings; postsecondary institution faculty providing 
health practitioner education programmes (informing 
prelicensure training); provincial colleges of health 
professionals (informing licensure bodies) and commu-
nity sexual health organisations across Canada. Quarterly 
briefs will engage team knowledge users, health profes-
sional participants, community organisation partners and 
appropriate colleagues and collaborators identified by 
them, to encourage informed updated approaches.
Patient and public involvement
Patient partners were involved in codesigning the 
research questions and outcome measures. Patients and 
representatives from community-based sexual health 
organisations across Canada were engaged through a 
face-to-face symposium in October 2016 and partici-
pated in regular monthly videoconference meetings. 
Through deliberation and dialogue, they discussed with 
the research team their perspectives on priority areas 
of study, and recruitment strategies for participants in 
rural and remote communities. As potential participants 
did not include patients or members of the public, only 
healthcare professionals were asked to assess the burden 
of the intervention and the time required to participate in 
research. Representatives from community-based sexual 
health organisations reviewed and provided feedback 
on our finalised research questions and design during 
the monthly videoconferences. They will be involved in 
disseminating study results to the public through info-
graphics shared in presentations and by email with their 
networks.
setting and participants
This national study will explore mifepristone medical abor-
tion in the context of primary care settings. In Canada, 
85% of Canadians have a regular medical doctor46 and 
provision of abortion by primary care providers is highly 
acceptable—the majority of surgical abortion providers 
are family physicians.47 For the purposes of this study, we 
define primary care settings as any service delivery envi-
ronment where a prescriber may provide primary care, 
including hospitals, abortion facilities, health centres, 
and private physician offices. Consistent with the initial 
Health Canada approval of the medication, we defined 
prescriber as a certified physician.
Group A: healthcare professionals engaged with mifepristone 
practice
Survey and interview enrolment for part 1 of the study is 
offered to all certified prescribers and pharmacists who 
intend to begin practice with mifepristone within the first 
year they are eligible to do so. As our past studies among 
abortion providers have recruited ~90% of eligible 
participants,3 46–48 we anticipate the cohort will be highly 
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representative. We estimate up to 1000 healthcare profes-
sionals would engage in mifepristone practice within the 
first year.
Group B: community of practice platform
The community of practice website will engage a wide 
range of interdisciplinary licensed healthcare profes-
sionals who are interested in providing mifepristone care, 
including certified prescribers and pharmacists. We will 
capture data from all members who enrol in the platform.
Group C: health policy, system, and services decision-makers and 
non-mifepristone providing healthcare professionals
We will recruit influential decision-makers across Canada 
who have the potential to impact health policy, system, 
and service factors found to be important determinants 
of implementation, as they are identified throughout the 
study. We will also engage healthcare professionals who 
do not choose to provide mifepristone, particularly if they 
are providing similar women’s health services, using key 
informant interviews or focus groups. These non-mife-
pristone providing healthcare professionals represent 
a population with an important viewpoint to assist us to 
understand barriers.
Group D: knowledge users engaged with iKT activities
Knowledge users have been involved in the research 
process from idea inception (questions and design 
elements posed by our knowledge user collaborators) 
to the development of this study to delineate facilitators 
and inform changes to the health system to facilitate 
implementation. They include health policy and practice 
decision-makers at the regional, provincial, and federal 
levels. We will invite these individuals and organisations 
to participate in data collection for the evaluation of our 
iKT activities.
outcomes
We will evaluate the effect of our mixed-methods, iKT 
implementation study on health system and policy deci-
sion-making, regulatory changes and on uptake of mife-
pristone. We will assess the uptake of mifepristone medical 
abortion by measuring the proportion of certified physi-
cians and pharmacists (per professional category) who 
are providing mifepristone care 1-year post-enrolment, at 
least once in the most recent 3 months in which they were 
in their usual practice. In addition, we will explore: (1) the 
number of communities or populations that have access 
to abortion compared with baseline; (2) the proportion 
of certified healthcare professionals providing mifepris-
tone at 6 months post-enrolment (by professional cate-
gory and by location, eg, urban vs rural, province) and (3) 
the volume of service provision at 1 year and correlates, 
particularly compared with baseline distribution of abor-
tion service providers and facilities.
Additionally, based on our mixed-methods analysis, we 
will develop an empirically driven framework of diffu-
sion of innovation in a health system that builds on and 
extends Greenhalgh et al’s theory.
We will also be flexible to identify and collect outcomes 
of interest to our policy-maker stakeholders, as part of 
our ongoing iKT approach.
data collection
Our project incorporates five key inter-related evaluation 
components (figure 2).
1. Continuous iKT activity interactions with key knowl-
edge users and decision-makers in health policy, health 
system, health professional organisation and regula-
tion, and health services delivery contexts.
2. Evaluation of iKT interactions with knowledge users 
and decision-makers, and relation to any associated 
health policy, system and service changes during the 
project.
3. Surveys and interviews among healthcare professionals 
who are interested in providing mifepristone care.
4. Quantitative and qualitative data collected from inter-
actions on a community of practice support platform 
for healthcare professionals, the CAPS-CPCA platform.
5. Interviews with key health system and services deci-
sion-makers and informants, and with healthcare pro-
fessionals who are engaged with women’s health but 
choose not to provide mifepristone care.
Surveys
We will distribute questionnaires among healthcare 
professionals engaged with mifepristone practice (group 
A) to measure factors related to adoption of mifepris-
tone abortion into practice49 50 and to explore constructs 
for diffusion of innovation. As appropriate, components 
of either or both sections will be administered at base-
line, 6 and 12 months. Participant demographics will be 
collected at baseline.
Section 1
Component surveys for the constructs of diffusion of inno-
vation will be administered. Constructs that are expected 
Figure 2 Canada’s Mifepristone Implementation Study, 
components of study design.
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to change over time will be examined at baseline and later 
time points (eg, task issues, skills); constructs relating to 
factors unknown at baseline (eg, characteristics of diffu-
sion) will be collected at 12 months.
Section 2
A 12-item questionnaire adapted from Légaré’s validated 
instrument51 based on the Godin framework will be 
administered at baseline, 6 and 12 months.
The survey instruments used in this study were devel-
oped and tested following methods described else-
where.51 52 Additionally, we conducted a rigorous process 
to develop and test the surveys used to measure imple-
mentation of mifepristone.40 The process for adapting 
and pilot testing the surveys for the present study is 
described in a forthcoming publication.
Interviews
Semistructured interviews will be conducted with a 
purposeful sample of the certified physicians and phar-
macists of group A, selected to represent diversity of: 
demographic characteristics (eg, gender, age, profes-
sion); factors related to adoption and diffusion of mife-
pristone practice (such as previous abortion practice and 
rural vs urban location); and positive and negative expe-
riences of abortion practice within 1-year post-training 
(to investigate the factors that affect implementation). 
Recruitment will be facilitated via the online survey. All 
healthcare professionals enrolled in the broader study 
will be asked, on completing the survey, if they would 
like to be contacted for a follow-up interview. Interested 
and eligible physician and pharmacist certificants will be 
contacted to arrange a follow-up interview in person or 
by phone. No interview participants will be recruited via 
group B, the community of practice, although certificants 
from group A may also be members of the community.
Health policy, system, and services decision-makers 
and non-mifepristone providing healthcare professionals 
(group C) and stakeholders involved in our iKT activ-
ities (group D) will be purposefully sampled based on 
preidentified factors49 53 (eg, profession, previous experi-
ence in abortion policy development or service provision, 
number of years as a knowledge user with the research 
team) and invited to participate in an interview. Group 
C participants will be invited via third-party recruitment 
with the assistance of the study’s knowledge user partners. 
Group D participants will be invited by email to partic-
ipate in an interview with our research team’s imple-
mentation scientist. As categories emerge from analysis 
of transcripts, theoretical sampling will be conducted to 
pursue emerging themes related to policy, system and/or 
service factors that influence implementation.
Interview questions will be theoretically informed by 
diffusion of innovation constructs, and Cook et al’s inter-
view guide22 will be pilot tested with a panel of researchers 
and clinicians prior to data collection. Interviews will be 
conducted until we achieve saturation in our data collec-
tion, sampling and analysis.54 In our data collection, we 
will seek ‘informational redundancy’55 (new data repeat 
what was expressed in previous data). We will recruit 
participants until no new themes or codes are identified 
in analysis and we have sufficient data to illustrate the 
core constructs of diffusion of innovation theory. We will 
also seek to recruit participants until our data sufficiently 
represent a range of the preidentified factors from our 
purposeful sampling strategies.
Data collection through the community of practice
Data from the community of practice platform will 
include reports of barriers and facilitators; responses to 
iterative one-question polls (based on surveys); questions 
to experts and participant usage statistics. Relationships 
within the community of practice and with the research 
team will enable identification of challenges, which will 
be shared with knowledge users via the iKT activities 
listed below.
Evaluation of iKT
To capture and understand the effectiveness of iKT strate-
gies, we will document our activities using the Workgroup 
for Intervention Development and Evaluation Research 
reporting checklist56 as recommended by Gagliardi et al.44 
Checklist constructs include: the goal of the activity and 
iKT partnership, mode of delivery, duration, frequency, 
participants and personnel. We will also document 
funding source, who initiated the activity and the theory 
underpinning the activity. Semistructured interviews with 
stakeholders, interactions on the community of practice 
platform and health system, policy, and service changes 
occurring in real time from our correspondence with 
knowledge users and decision-makers will help us docu-
ment the effect of our iKT strategies. As described above, 
these activities will be diverse and responsive to our knowl-
edge user audiences and may include invited evidence 
briefs, quarterly briefs, face-to-face meetings, email and 
phone communication, media interviews, newsletters and 
minutes of monthly videoconferences.
AnAlysIs
Quantitative data
Survey responses will be summarised descriptively over 
the entire sample. Stratified analysis will be performed 
for key determinants (ie, federal, provincial or local 
according to the issue). For provider characteristics, we 
will collect data on age, gender, rural versus urban setting, 
professional role (overall and by specialty), previous abor-
tion provision and independent practice versus working 
in a setting with two or more abortion providers. In light 
of Quebec’s well-developed support for rural and remote 
providers,48 57 we will perform a two-way stratification by 
(1) Quebec versus the rest of Canada and (2) rural/urban 
status. Additionally, location data will be collected on all 
participants to inform geo-mapping analyses on the emer-
gence and diffusion of mifepristone practice (and the 
subgroups by practitioner and with relation to provincial, 
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national or regional policies, systems and service struc-
tures) throughout Canada. We will analyse interactions of 
factors using multivariable logistic regression for binary 
(eg, provision of mifepristone) and ordinal (eg, barriers 
and facilitators) outcomes and linear multiple regression 
for volume of service. Emerging results will be used to 
inform iKT interactions throughout the project.
Following Morse et al’s guidance, our mixed-methods 
design is quantitatively driven with a simultaneous qual-
itative component.58 Our survey and CAPS analysis will 
inform the development of probing questions to ask 
during interviews. Analysis will be simultaneous using 
constant comparison methods; qualitative results will be 
used to enhance description of quantitative results and to 
corroborate knowledge from our different data sources 
to clarify key barriers and facilitators.
Qualitative data
Semistructured interviews, open-ended survey questions 
and CAPS website posted discussions will be subjected 
to thematic analysis59 by two qualitatively trained imple-
mentation scientists following confidential transcription. 
Analysis of qualitative data will involve these iterative, 
concurrent steps:
1. Developing a codebook by identifying contextual codes 
related to the research objective (identified inductive-
ly from the participant data). The two researchers will 
first code a sample of transcripts independently and 
compare their results to ensure accurate interpreta-
tion of the data. Discrepancies will be resolved through 
discussion with a third researcher.
2. Identifying individual, organisational and system pro-
cesses (including patterns, relationships and interac-
tions) between the codes.
3. Organising the processes into a theoretical framework 
informed by diffusion of innovation constructs. Rel-
evant domains for implementation will be identified 
through research team discussion and consensus.
4. Writing the analysis into a descriptive, explanatory nar-
rative that illuminates the barriers and facilitators to 
implementation of mifepristone abortion practice.
We will test and extend the theory of diffusion of inno-
vation. We will consider the frequency of constructs 
across the data, presence of conflicting constructs and 
perceived relevance of the constructs on implementation 
behaviour. Emerging results will be used to inform iKT 
interactions throughout the project to identify and miti-
gate addressable barriers.
Analysis of iKt activities data
We will analyse the iKT activity and outcome data, eval-
uating alignment with theoretical model constructs and 
addressable barriers identified through the research 
activities. Qualitative thematic analysis59 of stakeholder 
interviews will explore health system and policy factors 
that influence implementation at regional, provincial and 
federal levels, as well as the impact of iKT activities on 
implementation of mifepristone in primary care. As our 
additional iKT strategies will be emergent, dynamic and 
chosen in response to knowledge user and stakeholder 
need, we will also measure the impact of additional iKT 
strategies using appropriate methods and outcomes, selec-
tion of which will be guided by the Canadian Academy 
of Health Sciences Impact Framework.60 All interactions 
collected will be compared with any subsequent positive, 
negative or null changes to health system factors that 
influence implementation of mifepristone. The mech-
anisms related to any iKT activity will be delineated to 
assign scaled values for: the impetus (ie, knowledge user, 
researcher, media/public); the activity; the participants 
(categorised as per stakeholder groups); results and an 
assignment of an impact score for the effectiveness of the 
activity to contribute to changes in health policy, system 
or service delivery advancing mifepristone care.
EthICs And dIssEMInAtIon
All participants in this study will participate in full 
informed consent. For survey participants, completion 
and submission of the survey will constitute implied 
consent; for interview participants, a signed consent form 
will be required prior to participation.
dissemination plan
The study commenced on 1 January 2017 and its expected 
completion date is 1 January 2020. Full publication of the 
work will be sought in an international peer-reviewed 
journal. Findings will be disseminated to research partic-
ipants through newsletters and media interviews, and to 
policy-makers through invited evidence briefs, and face-
to-face presentations.
dIsCussIon
Knowledge and system improvements generated by this 
project have the potential to increase the proportion of 
all abortions that are provided medically. In turn, this 
could:
 ► Reduce need and systems costs for surgical abortion.
 ► Increase delivery of services closer to home, reducing 
travel and wait times.
 ► Increase delivery of services by the primary care 
provider, decreasing the need for referrals.
 ► Increase abortion safety, as medical abortion can be 
provided at the earliest and safest stages of pregnancy.
 ► Increase confidentiality and reduce the need for 
patients and healthcare providers to face interactions 
with protesters.
 ► Benefit hospitals by relieving pressure on operating 
room time and wait lists, while reducing stigma 
reported by abortion providers working in operating 
room settings.
The proposed timely research, undertaken by our 
well-established cross-sectoral national network, the 
Contraception and Abortion Research Team-Groupe de 
recherche sur l’avortement et la contraception,53 61 62 will 
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identify the determinants of uptake of medical abortion as 
this health service innovation is implemented in Canada. 
We aim to understand, and in real time to address, 
barriers and facilitators to adoption of this new clinical 
practice. In addition, we have planned separate studies 
to assess health outcomes and costs of mifepristone using 
linked administrative datasets, as well as investigate the 
role of nurse practitioners and registered midwives in 
the provision of medical abortion in Canada. Knowledge 
about the effect of the full range of health policy, system 
and service determinants on access to mifepristone abor-
tion is needed to realise the potential to increase equi-
table, safe, confidential abortion care closer to home for 
women throughout Canada. Findings also will contribute 
to understanding the mechanisms of iKT relationships 
and activities that have a meaningful effect on the uptake 
of evidence into policy and practice.
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